Early access
Sign in
Taking people in United StatesNo phase

NEPTUNE Match Study

Key facts

Who runs it
University of Michigan
Where
Ann Arbor, Atlanta, Baltimore, Chapel Hill, Charlotte, Chicago, Cleveland, Kansas City, New Hyde Park, New York, Philadelphia, Seattle, and Spokane, United StatesSee the 16 sites
Trial code
Status
Recruiting
People taking part
375 people, planned
Started
2 May 2022
Expected to end
30 Dec 2029
Type of study
Interventional
Treatments tested
  • Communication
Record updated
10 November 2026

Who can take part

Age
1 year to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Consented and eligible participants in the biopsied or non-biopsied cohorts of the NEPTUNE observational study
  • Must be potentially eligible for the NEPTUNE Match partnering trials (e.g. if no trial is enrolling a participant under age 6, those under 6 are not eligible); Note: NEPTUNE Match partnering trials and associated eligibility criteria are expected to be dynamic and change as trial protocols are developed, activated, and amended
  • Regular nephrology healthcare provided at a NEPTUNE study site
  • Willing and able to consent, and as appropriate assent, to participate in NEPTUNE Match

Who cannot take part

  • Currently non-NEPTUNE observational study participants are not eligible to be matched to a clinical trial using these biomarker assessments
  • Non-English or non-Spanish speaking

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 80 years old?

Where in United States

  • University of MichiganAnn Arbor, United StatesContact: Hailey E Desmond, MSEnrolling by invitation
  • Emory University Hospital - Children's Hospital of AtlantaAtlanta, United StatesContact: Emily YunTaking people
  • Johns Hopkins MedicineBaltimore, United StatesContact: MIahje WilliamsTaking people
  • University of North Carolina, Chapel HillChapel Hill, United StatesContact: Anne FromentTaking people
  • Medical University of South CarolinaCharlotte, United StatesContact: David Selewski, MD, MS (principal investigator)Taking people
  • John H Stroger Jr Hospital of Cook CountyChicago, United StatesContact: Mathew ItteeraTaking people
  • Cleveland Clinic FoundationCleveland, United StatesContact: Stefanie LarsonTaking people
  • Children's Mercy HospitalKansas City, United StatesContact: Kelsey MarkusTaking people
  • University of Kansas Medical CenterKansas City, United StatesContact: Catherine CreedTaking people
  • Northwell/Cohen's Children's HospitalNew Hyde Park, United StatesContact: Suzanne Vento, BSNTaking people
  • Columbia University Medical CenterNew York, United StatesContact: Anup PradhanTaking people
  • Hospital of the University of PennsylvaniaPhiladelphia, United StatesContact: Krishna Kallem, MSTaking people
  • Temple UniversityPhiladelphia, United StatesContact: Zoe PfefferTaking people
  • Seattle Children's HospitalSeattle, United StatesContact: Emily PaoTaking people
  • University of Washington Medical CenterSeattle, United StatesContact: Linda Manahan, BSNTaking people
  • Providence Sacred Heart Medical CenterSpokane, United StatesContact: Kelli KuykendallTaking people

About the trial

What the trial wants to find out

NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.

The group in the trial

  • NEPTUNE Match ParticipantsOther group

    Approximately 375 participants will be consented from the NEPTUNE observational study with age and demographic groups representing the patient population in the NEPTUNE study site geographical areas. NEPTUNE observational cohort eligibility includes: participants in NEPTUNE observational cohort A are of any age and have a biopsy-confirmed diagnosis of Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), or Membranous Nephropathy (MN). Participants in NEPTUNE observational cohort B have documented NS based on proteinuria, serum albumin, and/or edema with age of onset less than 19 years.

    Treatment: Communication

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Implementing Precision Medicine for Glomerular Diseases in the Nephrotic Syndrome Study Network (NEPTUNE)
Fit questions
Built from NCT04571658, who can take part
Record updated
10 November 2026